Showing Results for
- Academic Journals (28)
Search Results
- 28
Academic Journals
- 28
-
From:Nature Biotechnology (Vol. 39, Issue 6) Peer-ReviewedThe not-for profit foundation n-Lorem seeks to provide experimental antisense oligonucleotide treatments to patients with ultra-rare disease free for their entire lifetime. Author(s): Stanley T. Crooke 1 Author...
-
From:Nature Biotechnology (Vol. 39, Issue 6) Peer-ReviewedOvercoming limitations of previous fluorescent light-up RNA aptamers for super-resolution imaging, we present RhoBAST, an aptamer that binds a fluorogenic rhodamine dye with fast association and dissociation kinetics....
-
From:Nature Biotechnology (Vol. 39, Issue 6) Peer-ReviewedAuthor Affiliations: Gut microbiome health company Viome has repurposed its mRNA analysis and machine learning technology to develop a saliva test to screen for head and neck cancers. Viome's diagnostic test, which...
-
From:Nature Biotechnology (Vol. 39, Issue 6) Peer-ReviewedNature Biotechnology asks a selection of leaders from across biotech to look at the future of the sector and make some predictions for the coming years. Author(s): Abasi Ene Abong 1 , Katrine Bosley 2 , Charlotte...
-
From:Nature Biotechnology (Vol. 39, Issue 6) Peer-ReviewedAuthor Affiliations: Canadian regulators have started a rolling review of a plant-made COVID-19 vaccine that has produced strong immune responses in a mid-stage clinical trial. Medicago, based in Quebec City, Canada,...
-
From:Nature Biotechnology (Vol. 39, Issue 6) Peer-ReviewedOrganoid models of early tissue development have been produced for the intestine, brain, kidney and other organs, but similar approaches for the heart have been lacking. Here we generate complex, highly structured,...
-
From:Nature Biotechnology (Vol. 39, Issue 6) Peer-ReviewedNew initiatives in N-of-1 drug development and clinical trial design offer the possibility of therapies for ultra-rare disease patients who have been long neglected by the drug industry. Author Affiliations:...
-
From:Nature Biotechnology (Vol. 39, Issue 6) Peer-ReviewedAuthor(s): Sebastian M. Pfotenhauer 1 , Nina Frahm 1 , David Winickoff 2 , David Benrimoh 3 4 , Judy Illes 5 , Gary Marchant 6 Author Affiliations: (1) Munich Center for Technology in Society (MCTS) and TUM School of...
-
From:Nature Biotechnology (Vol. 39, Issue 6) Peer-ReviewedIn coronavirus disease 2019 (COVID-19), hypertension and cardiovascular diseases are major risk factors for critical disease progression. However, the underlying causes and the effects of the main anti-hypertensive...
-
From:Nature Biotechnology (Vol. 39, Issue 6) Peer-ReviewedAuthor Affiliations: Carl June is a co-founder of Tmunity Therapeutics and a professor in immunotherapy at the University of Pennsylvania, where he also runs a lab. His conversation with Nature Biotechnology includes...
-
From:Nature Biotechnology (Vol. 39, Issue 6) Peer-ReviewedNonlinear data visualization methods, such as t-distributed stochastic neighbor embedding (t-SNE) and uniform manifold approximation and projection (UMAP), summarize the complex transcriptomic landscape of single cells...
-
From:Nature Biotechnology (Vol. 39, Issue 6) Peer-ReviewedAuthor Affiliations: Karl Deisseroth and Viviana Gradinaru speak with senior editor Markus Elsner about the state of optogenetics and how it can be used to better understand and treat human disease....
-
From:Nature Biotechnology (Vol. 39, Issue 6) Peer-ReviewedIs the oncogene MYC upregulated or hyperactive? In the majority of human cancers, finding agents that target c-MYC has proved difficult. Here we report specific bacterial effector molecules that inhibit cellular MYC...
-
From:Nature Biotechnology (Vol. 39, Issue 6) Peer-ReviewedComputational approaches for drug discovery, such as quantitative structure-activity relationship, rely on structural similarities of small molecules to infer biological activity but are often limited to identifying new...
-
From:Nature Biotechnology (Vol. 39, Issue 6) Peer-ReviewedRecent moves of note in and around the biotech and pharma industries. Author Affiliations: Clinical-stage biopharma Humanigen has announced the appointment of Adrian Kilcoyne (photo) to the newly created role of...
-
From:Nature Biotechnology (Vol. 39, Issue 6) Peer-ReviewedResearchers hope that antisense oligo clinical trial failures in Huntington's will shed light on mechanism and drug biodistribution and galvanize ongoing drug development efforts. Author(s): Cormac Sheridan 1 Author...
-
From:Nature Biotechnology (Vol. 39, Issue 6) Peer-ReviewedAuthor(s): Lika Drakhlis 1 , Santoshi Biswanath 1 , Clara-Milena Farr 1 , Victoria Lupanow 1 , Jana Teske 1 , Katharina Ritzenhoff 1 , Annika Franke 1 , Felix Manstein 1 , Emiliano Bolesani 1 , Henning Kempf 1 11 ,...
-
From:Nature Biotechnology (Vol. 39, Issue 6) Peer-ReviewedA citation map connecting patents to biomedical publications provides insights that can be used to better evaluate productivity, diversity and translational impact. Author(s): Anoop Manjunath 1 , Hongyu Li 2 , Shuchen...
-
From:Nature Biotechnology (Vol. 39, Issue 6) Peer-ReviewedAuthor Affiliations: A high-end coffeehouse chain and an agbiotech in Argentina have joined forces to offer consumers products baked with the first approved drought-resistant GM wheat. The agreement between Bioceres...
-
From:Nature Biotechnology (Vol. 39, Issue 6) Peer-ReviewedModern experimental technologies can assay large numbers of biological sequences, but engineered protein libraries rarely exceed the sequence diversity of natural protein families. Machine learning (ML) models trained...